Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

May S.K. Sutherland, PhD, Changpu Yu, MD, Carol Morris-Tilden, Timothy S. Lewis, PhD, Jamie B. Miyamoto, Julie A. McEarchern, PhD, Ezogelin Oflazoglu, PhD, Hanspeter Gerber, PhD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2007) 110 (11): 919.

https://doi.org/10.1182/blood.V110.11.919.919

Published: 2007

Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2006) 108 (11): 1995.

https://doi.org/10.1182/blood.V108.11.1995.1995

Published: 2006

Journal Articles

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

Evdoxia Hatjiharissi, MD, Allen W. Ho, Lian Xu, Kelly E. O’Connor, Zachary R. Hunter, Daniel D. Santos, MD, Robert Manning, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Christopher J. Patterson, Julie A. McEarchern, PhD, Che-Leung Law, PhD, Iqbal S. Grewal, PhD, Nikhil C. Munshi, MD, PhD, Steven P. Treon, MD, PhD

Blood (2006) 108 (11): 2490.

https://doi.org/10.1182/blood.V108.11.2490.2490

Published: 2006

Journal Articles

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

Che-Leung Law, PhD, Julie A. McEarchern, PhD, Charles G. Cerveny, MS, Leia M. Smith, PhD, Albina Nesterova, MS, Kristine A. Gordon, BS, Iqbal S. Grewal, PhD, Alan F. Wahl, PhD

Blood (2005) 106 (11): 1476.

https://doi.org/10.1182/blood.V106.11.1476.1476

Published: 2005

Journal Articles

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Julie A. McEarchern, PhD, Charlotte McDonagh, PhD, Allen Ho, BA, Yu-Tzu Tai, PhD, Leigh Francisco, BS, Kerry Klussman, BS, Carol Morris-Tilden, BS, Kristine Gordon, BS, Ezogelin Oflazoglu, PhD, Kim Kissler, Nikhil Munshi, MD, Kenneth C. Anderson, MD, Steven P. Treon, MD, PhD, Paul Carter, PhD, Alan F. Wahl, PhD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2005) 106 (11): 1591.

https://doi.org/10.1182/blood.V106.11.1591.1591

Published: 2005

NARROW

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only